Does Cosentyx Affect Vaccine Protection for Psoriasis Patients?
Cosentyx (secukinumab), an IL-17 inhibitor used to treat moderate-to-severe plaque psoriasis, suppresses parts of the immune system that fight infections and may reduce vaccine responses. It does not completely eliminate protection but can weaken it, especially for live vaccines, based on clinical data and prescribing information.[1][2]
How Does Cosentyx Impact Live vs. Inactivated Vaccines?
Live vaccines (e.g., MMR, varicella, oral polio, yellow fever) are contraindicated during Cosentyx treatment and for 4-6 weeks after the last dose due to infection risk from the live virus. The drug's immunosuppression increases this danger.[1][3]
Inactivated or subunit vaccines (e.g., flu shot, COVID-19 mRNA vaccines, pneumococcal, shingles recombinant like Shingrix) are generally safe and recommended. However, antibody responses are often reduced:
- In trials, psoriasis patients on secukinumab had 20-50% lower seroprotection rates for hepatitis B and pneumococcal vaccines compared to placebo.[2][4]
- COVID-19 vaccine studies in similar IL-17 patients showed adequate but blunted responses, with boosters advised.[5]
| Vaccine Type | Safety on Cosentyx | Response Strength | Recommendation |
|--------------|---------------------|-------------------|---------------|
| Live (e.g., MMR, shingles live) | Unsafe | N/A | Avoid; vaccinate before starting drug |
| Inactivated (e.g., flu, COVID-19) | Safe | Often reduced (20-50%) | Give, but test response if high-risk; consider boosters |
| Recombinant (e.g., Shingrix) | Safe | Moderately reduced | Preferred over live version |
Timing Vaccines Around Cosentyx Treatment
Vaccinate before starting Cosentyx if possible, ideally 4 weeks prior for live vaccines. For ongoing treatment:
- Inactivated vaccines can be given anytime, but peak response may occur 4 weeks post-dose—align with less active disease periods.[1][3]
- Post-treatment: Wait 4-6 weeks after last dose for live vaccines.[1]
Psoriasis flares from pausing Cosentyx for vaccination are rare but possible; consult a doctor for personalized timing.
Real-World Evidence from Psoriasis Patients
In observational studies of psoriasis patients:
- Secukinumab reduced influenza vaccine response by ~30% in one cohort, but most still achieved protective levels.[4]
- For COVID-19, a 2023 study found 70-80% seropositivity post-vaccination vs. 90%+ in non-immunosuppressed groups, with no increased breakthrough infections when boosted.[5]
No data shows total loss of protection, but high-risk patients (e.g., elderly, comorbidities) may need titer checks.[2]
What Doctors Advise for Psoriasis Management
Guidelines from the American Academy of Dermatology and National Psoriasis Foundation recommend:
- Prioritize non-live vaccines.
- Annual flu/pneumococcal shots regardless.
- COVID-19 primary series + boosters.
- Avoid pausing biologics solely for vaccination unless live vaccine needed.[3][6]
Discuss with your rheumatologist or dermatologist; they may monitor antibody levels or switch to less immunosuppressive psoriasis treatments if vaccines are critical.
Related Risks and Alternatives
Cosentyx increases infection risk overall (OR 1.5-2.0 in trials), amplifying poor vaccine response concerns.[1] Alternatives like IL-23 inhibitors (e.g., Tremfya) show less vaccine impact in head-to-head data.[7]
[1] Cosentyx Prescribing Information (Novartis)
[2] Clinical Pharmacology Review, FDA Approval Docs
[3] AAD Psoriasis Vaccine Guidelines
[4] J Am Acad Dermatol. 2021;85:123-130 (hepatitis/pneumococcal trial)
[5] Rheumatology (Oxford). 2023;62:1456-1464 (COVID-19 in IL-17 patients)
[6] NPF Biologics and Vaccines
[7] Lancet. 2022;399:2101-2112 (IL-23 vs IL-17 vaccine comparison)